SAGE Therapeutics
Develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 16123 % | (99 %) | 22 % | 1025 % | (52 %) | 100 % | 44 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 58 % | (7307 %) | (7117 %) | (592 %) | (940 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 54 % | (7259 %) | (6932 %) | (626 %) | (971 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 26 % | 4489 % | 4244 % | 412 % | 548 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Sage Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies aimed at transforming the lives of individuals suffering from debilitating brain disorders. The company focuses on creating novel treatments for conditions within the realms of depression, neurology, and neuropsychiatry. Sage Therapeutics operates in the pharmaceutical and biotechnology market, primarily serving patients and healthcare providers who are in need of advanced brain health solutions. The business model revolves around extensive research and development (R&D) programs, clinical trials, and strategic partnerships, such as their collaboration with Biogen, to bring groundbreaking medications to market. Revenue is generated through the commercialization of these therapies, licensing agreements, and milestone payments from partners. Sage Therapeutics' mission is to make medicines that matter, ensuring that patients can achieve better health outcomes sooner.
Keywords: biopharmaceutical, brain health, depression, neurology, neuropsychiatry, innovative therapies, clinical trials, R&D, Biogen partnership, commercialization.